Thermo Fisher Scientific Inc. (NYSE:TMO) is one of the best stocks to invest in, according to billionaire D.E. Shaw. On October 29, Thermo Fisher announced plans to buy Clario, a private data ...

(Reuters) - Thermo Fisher said on Wednesday it would buy privately held data management company Clario for up to $9.4 billion, strengthening its clinical trial research business amid a strong rebound ...

Thermo Fisher Scientific has completed the acquisition of Clario, a provider of endpoint data solutions for clinical trials, in an $8.875bn cash deal. In addition to the initial purchase price, Thermo ...

Thermo Fisher Scientific, already a big player in providing services to the biopharmaceutical industry, is adding to its technology capabilities with the $9 billion acquisition of clinical trial ...

Thermo Fisher has also agreed to pay up to $400 million of earn-out payments based on the performance of the business in 2026 and 2027 The transaction is expected to be completed by the middle of 2026 ...

Attractive return profile given high growth and strong margin profile of Clario, and meaningful synergies – reflecting the company’s disciplined approach to capital deployment Thermo Fisher Scientific ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The largest medical device maker ...

Expected to be immediately accretive to Adjusted Earnings Per Share (EPS)¹ after close Attractive return profile given high growth and strong margin profile of Clario, and meaningful synergies - ...

Thermo Fisher Scientific Inc. agreed to acquire Clario Holdings Inc., a privately held maker of drug trial software, for about $8.9 billion in cash. The deal will give Thermo Fisher, a provider of ...

Further strengthens Thermo Fisher’s position as the trusted partner to pharma and biotech customers, delivering important customer benefits Attractive return profile given high growth and strong ...